MAGEA3 and melanoma: The active immune class shares high similarity with melanoma patients who responded to treatment with MAGE-A3 (Figure 3B, bottom left) and BALB/c mice who responded to treatment with anti-CTLA-4 (Figure 3B, bottom right).